More than 100 cancer patients have received an innovative form of radiation therapy at the S. Lee Kling Center for Proton Therapy in the center’s first year of operation.
Proton therapy is a precise form of radiation that targets tumors while sparing surrounding healthy tissues, making it ideal for treating pediatric cancer patients, as well as adults with tumors near the heart, brain or in other sensitive locations. The new technology delivers the same targeted, noninvasive treatments as conventional proton systems but is considerably smaller in size and costs less.
“We offer proton therapy to patients we think would benefit from this particular technology, such as children and those with tumors in the brain or around the spinal cord,” said Jeffrey Bradley, MD, a Washington University radiation oncologist and director of the S. Lee Kling Center for Proton Therapy. “We offer a full suite of cancer treatments, and this technology helps to meet the health-care needs of the patients we serve.”
Since December 2013, the new system:
- Has delivered more than 6,700 clinical proton treatment fields to 118 patients. (One treatment field equals the use of a single proton beam. Each patient receives two or three treatment fields per therapy session.) Of those patients, about 25 percent were children and 75 percent were adults;
- Has addressed a variety of complex tumors. Of adult tumors treated, 43 percent were in the brain, 27 percent were in the lungs, 11 percent were in the prostate and 8 percent were in the esophagus; and
- Has treated more than 20 patients in a single day.
Lawrence Barry, 62, of St. Louis, recently finished proton therapy treatments at Siteman for a rare brain tumor. The tumor had been causing severe headaches and memory loss until it was surgically removed. His lead physician, Washington University radiation oncologist Clifford Robinson, MD, recommended proton therapy instead of X-ray radiation as a follow-up treatment.
“For every patient, we make a thoughtful decision about whether proton therapy is the best option,” said Robinson, assistant professor of radiation oncology at Washington University. “In Mr. Barry’s case, we decided to use protons because it would decrease substantially the radiation dose to his heart, lungs and bowels. In addition, proton therapy reduces the side effects sometimes caused by X-ray radiation, such as such as nausea, diarrhea and fatigue.”
A superconducting synchrocyclotron proton accelerator is a key component of the proton therapy system. The relatively small size of the device allows it to fit in a single room that isn’t much larger than a traditional radiation therapy room. The cost of this single-vault proton therapy system was about $25 million. That represents a fraction of the investment needed for traditional proton therapy systems, which typically are housed in football field-sized buildings and cost more than $150 million.
Littleton, Mass.-based Mevion Medical Systems developed and manufactured the technology, called the MEVION S250 Proton Therapy System. Radiation oncologists and physicists at Washington University worked with Mevion to develop and refine the proton therapy technology.
The proton therapy center was named after the late S. Lee Kling, a visionary St. Louisan who traveled to the East Coast to receive proton therapy for an eye tumor. Kling, a former chairman of The Foundation for Barnes-Jewish Hospital’s board of directors, believed the therapy should be more accessible and available to patients in St. Louis. As a result, Kling, along with family and friends, established the S. Lee Kling chair in radiation oncology — held by Bradley — to help lead the proton center’s development and to conduct research into the most effective ways to use this new technology.
The center serves the St. Louis region and the Midwest. The next closest location offering proton therapy is in the Chicago area, about 280 miles away.
Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.
Siteman Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center in Missouri, is ranked among the top cancer facilities in the nation by U.S. News & World Report. Comprising the cancer research, prevention and treatment programs of Barnes-Jewish Hospital and Washington University School of Medicine, Siteman is also Missouri’s only member of the National Comprehensive Cancer Network.